North York General Hospital

Toronto, Ontario M5S1B6

7 studies enrolling now · 30 studies all time

What they study most

Aging, Antimicrobial, Bacteremia, Breast Cancer, Breast Carcinoma, Carcinoma, Transitional Cell, Cognition, Colon Adenocarcinoma, Critically Ill, Death; Neonatal, Diffuse Large B-Cell Lymphoma, Down Syndrome

Studies at this site

• Pridopidine Phase 3 Study in Huntington's Disease — Recruiting now
• A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) — Recruiting now
• Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease — Recruiting now
• HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease — Recruiting now
• Regeneration of Acutely Injured Nerves With Temporary Electrical Stimulation — Recruiting now
• The TELENEO Trial: A Multicenter Trial of Telemedicine for Advanced Neonatal Resuscitations in Community Hospitals — Recruiting now
• Specimen Collection from Pregnant Women At Increased Risk for Fetal Aneuploidy — Recruiting now
• Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort — Recruiting now
• Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers — Completed
• Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy — Running, not enrolling
• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer — Running, not enrolling
• No Opioids vs. Minimal Opioids Following Inguinal Hernia Repair — Running, not enrolling
• Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery — Running, not enrolling
• Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma — Completed
• Breast Cancer WEight Loss Study (BWEL Study) — Running, not enrolling
• A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) — Completed
• Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness — Completed
• A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection — Stopped early
• Natural History Study in Huntington Disease Gene Expansion Carriers (HDGECs) - SHIELD HD — Status unconfirmed
• VAlidation of a Lower Cost aneUploidy scrEen — Completed
• A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM) — Completed
• A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer — Completed
• A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA) — Stopped early
• Condition of Submental Fullness and Treatment Outcomes Registry — Completed
• Cognition in the Study of Tamoxifen and Raloxifene — Completed
• Clinical Evaluation of the SEQureDx T21 Test In High Risk Pregnancies — Completed
• A New Prenatal Blood Test for Down Syndrome — Completed
• A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease — Completed
• Evaluation of Viral Shedding Patterns and Clinical Outcomes of Influenza Patients — Completed
• A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease — Completed